Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST). Update May 2022

Rothschedl, E. and Wolf, S. (2021): Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST). Update May 2022. Oncology Fact Sheet Nr. 62.

[thumbnail of Oncology Fact Sheet Nr.62_2nd Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
105kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WI Digestive system > WI 250 Oesophagus WI Digestive system > WI 300-387 Stomach WI Digestive system > WI 400-560 Intestines WI Digestive system > WI 600-650 Anus. Rectum
Language:	English
Series Name:	Oncology Fact Sheet Nr. 62
Deposited on:	15 Oct 2021 15:15
Last Modified:	16 May 2022 09:31

Repository Staff Only: item control page